8-K: Kiromic BioPharma Secures $1 Million in Funding Through Convertible Note Offering

Kiromic BioPharma has entered into a material definitive agreement, issuing a $1 million senior secured convertible promissory note to an accredited investor to support its CAR-T cell therapy development and for general corporate purposes.

Summary

• Kiromic BioPharma issued a 25% Senior Secured Convertible Promissory Note for $1,000,000 to an accredited investor on January 28, 2025.
• The note matures on January 28, 2026, with a 25% annual interest rate, potentially increasing to 27% upon default.
• The holder can convert the note into common stock starting February 28, 2025, at 90% of the 5-day VWAP, subject to a 19.99% beneficial ownership limitation.
• The note is secured by the company's fixtures, equipment, and intellectual property.
• The investor now holds a total of $13.2 million in promissory notes, plus preferred stock in Series C, D, and E.
• The proceeds will be used for the continued development of the multi-indication allogeneic CAR-T cell therapy and for other general corporate purposes.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company secures funding, the high interest rate and potential dilution are concerns. The focus on CAR-T cell therapy development is a positive sign.

Positives

• Kiromic BioPharma secures $1 million in funding, strengthening its financial position.
• The funding is earmarked for the development of CAR-T cell therapy, potentially advancing its clinical programs.
• The convertible note structure allows for potential equity upside for the investor while providing Kiromic with capital.
• The company retains the option to prepay the note without penalty, offering financial flexibility.

Negatives

• The high interest rate of 25% (potentially 27% upon default) increases Kiromic's financial obligations.
• The conversion of the note could dilute existing shareholders' equity.
• The security interest granted on the company's assets could limit its ability to secure future financing.
• Failure to deliver conversion shares on time results in significant cash penalties for the company.

Risks

• Failure to make payments on the note could trigger an event of default, potentially leading to acceleration of the debt.
• The company's reliance on a single investor for a significant portion of its funding exposes it to concentration risk.
• Delays in the registration of conversion shares could result in penalties and impact the investor's ability to sell the shares.
• The beneficial ownership limitation may restrict the investor's ability to fully convert the note.

Future Outlook

The company intends to use the proceeds from the note for the continued development of its multi-indication allogeneic CAR-T cell therapy and for other general corporate purposes, suggesting a focus on advancing its clinical programs and supporting its operations.

Management Comments

• Pietro Bersani, Chief Executive Officer, signed the report on behalf of Kiromic BioPharma, Inc.

Industry Context

This financing is typical for small biotech companies that need capital to fund research and development. Convertible notes are a common instrument, allowing investors to participate in potential upside while providing debt financing.

Comparison to Industry Standards

• The 25% interest rate is relatively high, reflecting the risk associated with investing in a small, development-stage biotech company.
• Comparable companies might secure funding through venture capital, private equity, or public offerings, depending on their stage and market conditions.
• The terms of the convertible note, including the conversion price and beneficial ownership limitation, are standard features designed to protect both the company and the investor.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into common stock.
• Employees may benefit from the continued funding of the company's research and development programs.
• The company's ability to meet its financial obligations will impact its suppliers and creditors.
• Customers (patients) may benefit from the advancement of CAR-T cell therapy.

Next Steps

• Kiromic BioPharma will use the proceeds to continue developing its CAR-T cell therapy.
• The company will need to manage its debt obligations and potential dilution from the convertible note.
• The company needs to file a registration statement for the resale of the Conversion Shares no later than thirty (30) calendar days after the Conversion Share Delivery Date.
• The company needs to have the Registration Statement declared effective no later than seventy (70) calendar days following the Conversion Share Delivery Date.

Key Dates